Nanomedicines for the prevention and treatment of infectious diseases / Vandana B. Patravale, Abhijit A. Date, Anil B. Jindal, editors.
Patravale, Vandana.; Date, Abhijit A.; Jindal, Anil B.
2023
RC112
Available Online

Linked e-resources

Linked Resource Online Access
Concurrent users Unlimited
Authorized users Authorized users
Document Delivery Supplied Can lend chapters, not whole ebooks

Details

Title Nanomedicines for the prevention and treatment of infectious diseases / Vandana B. Patravale, Abhijit A. Date, Anil B. Jindal, editors.
ISBN 9783031390203 (electronic bk.)
3031390202 (electronic bk.)
3031390199
9783031390197
DOI https://doi.org/10.1007/978-3-031-39020-3
Publication Details Cham : Springer, 2023.
Language English
Description 1 online resource (415 p.).
Item Number 10.1007/978-3-031-39020-3 doi
Call Number RC112
Dewey Decimal Classification 616.9
Summary The COVID-19 pandemic has altered the world and reiterated the perpetual need for the development of effective strategies for the prevention and treatment of infectious diseases. While globally prevalent infectious diseases receive extensive attention in terms of drug development and delivery, the neglected and/or emerging infectious diseases that affect developing countries are often overlooked. From the commercialization of AmBisome to the emergency authorization of mRNA-based vaccines, nanotechnology has played a vital role in the prevention and treatment of infectious diseases. More importantly, nanotechnology has enabled the effective utilization of existing armamentarium against infectious diseases leading to improved therapeutic outcomes with a concomitant reduction in the side effects associated with anti-infective agents. In particular, nanotechnology can bring about a paradigm shift in the management of neglected and emerging infectious diseases and may compensate for the lack of drug discovery efforts. This book addresses an unmet need in pharmaceutical and medical education. This book provides a comprehensive and up-to-date overview of the latest advancements in nanomedicine, which show great potential for preventing and treating infectious diseases. Covering a wide range of topics, it explores various formulation strategies for combating microbial, fungal, parasitic, and viral infections. The book emphasizes the advantages of nano-scale vaccines over traditional ones and discusses their production. It also examines feasible treatment approaches for diseases like malaria, trypanosomiasis, candidiasis, Hepatitis B, HIV, and the ongoing COVID-19 pandemic. Additionally, it highlights the role of nano-adjuvants in vaccine development, as well as the use of peptide antibiotics and pulmonary delivery of drugs, which open up new possibilities in fighting infectious diseases. Furthermore, the book explores the critical role of nanomedicine in addressing veterinary parasitic infections. The emergence of nanotechnology has led to novel strategies for diagnosing, treating, and preventing parasitic infections in animals.
Note 12 Challenges Encountered by Nanomedicines Before Entering the Lungs Are
Includes index.
Access Note Access limited to authorized users.
Source of Description Online resource; title from PDF title page (SpringerLink, viewed November 14, 2023).
Added Author Patravale, Vandana.
Date, Abhijit A.
Jindal, Anil B.
Series AAPS advances in the pharmaceutical sciences series ; v. 56.
Available in Other Form Nanomedicines for the Prevention and Treatment of Infectious Diseases
Linked Resources Online Access
Record Appears in Online Resources > Ebooks
All Resources
Intro
Preface
Acknowledgements
Contents
Contributors
About the Editors
Nanocarriers for Delivery of Peptide Antibiotics
1 Introduction
2 ABPs: An Imperative Subset of AMPs
2.1 Principal Characteristics and Biological Role of ABPs
3 Role of Nanotechnology in Delivering ABPs
3.1 Inorganic Nanocarriers
Mesoporous Silica Based Nanocarriers
Mesoporous Titania Based Nanocarriers
3.2 Polymeric Nanocarriers
PLGA Based Nanocarriers
Chitosan-Based Nanocarriers
Polymeric Nanofibres
3.3 Lipidic Nanocarriers

Cubosomes (Cubic Phase Lipid Nanoparticles)
Solid Lipid Nanoparticles (SLN)
Nanostructured Lipid Carriers (NLC)
Liposomes
3.4 Self-Assembled Nanocarriers
Self-Assembled ABPs
Micelles
3.5 Covalently Conjugated ABPs
Covalent Conjugation of ABP with Biomacromolecules
Covalent Conjugation of ABP with Synthetic Polymers
4 Opportunities and Challenges for Nanocarrier-Based ABP Delivery
5 Commercialisation and Clinical Development of ABPs
6 Summary
References
Nanomedicines for the Pulmonary Delivery of Antibiotics
1 Introduction
1.1 Lungs as Delivery Sites

1.2 Epidemiology of Pulmonary Infections
1.3 Chronic Lung Conditions as a Nidus of Infections
1.4 Opportunistic Lung Infections
1.5 Long COVID
1.6 Nanomedicine APIs
1.7 Nano-DDS and Multidrug-Resistant Strains
1.8 Nano-Periodic Property and Critical Nanoscale Design Parameters
1.9 Mode of Delivery of Inhaled Antimicrobial APIs
1.10 Aim of This Book Chapter
2 Anatomy and Physiology of the Respiratory System
2.1 Physiology of Gas and Particle Exchange
2.2 The Blood-Gas Barrier
2.3 Diffusion in Diseased Lungs

3 Factors Influencing Nanoparticulate Antimicrobial Delivery
3.1 Effect of Particle Size
3.2 Reduction Methods
3.3 Deposition Versus Stability
3.4 Formulations
4 Mechanics of Deposition of Nanoparticle Antimicrobials
4.1 Impaction
4.2 Gravitational Sedimentation
4.3 Deposition by Brownian Diffusion (BD)
4.4 Turbulent Mixing
4.5 Interception
4.6 Electrostatic Precipitation
5 Factors Affecting the Efficacy of Aerosolized Nanoantibiotics
6 Etiologies of Respiratory Infections
7 Characteristics of Inhaled NP Antibiotics

7.1 Nanoparticle (NP)-Based Antibiotics: The CF-PA Tobramycin (Tbm) Model
7.2 Advantages
7.3 Challenges to Making Dry Powder NPs
7.4 Methods of NP Preparation: Examples
7.5 Modifications in NPs for Better Functions
7.6 Bypassing of Phagocytes
7.7 Physicochemical Characterization
8 Clinical Indications of Inhaled Antimicrobials
8.1 Other Aerosolized Antibacterial Medications
9 Role of Aerosolized Antimicrobials in Multidrug-Resistant Strains
10 Inhaled Antibiotics in SARS-CoV-2-Infected Patients
10.1 Nebulizers
11 Importance of the Pharmacokinetic Phase

Browse Subjects

Show more subjects...

Statistics

from
to
Export